In AML cohort, 39 subjects were evaluable for the presence of chromosomal abnormalities, and 12 of them (31%) had WT1 levels < cut-off at diagnosis, while remaining 27 subjects (69%) had increased levels (Figure 4A). Here, WT1 is linked to acute myeloid leukemia.